上市后药物安全性监测 Post marked monitoring of drug safety
对抗疟药物的上市后监测和药物警戒。
Post-Marketing Surveillance and Pharmacovigilance of antimalarials.
最近，为了明确新批准药物的安全性，一直有呼声要求FDA投资并监测新药的上市后4期研究。
Recently, there have been calls for the FDA to fund and oversee phase 4 postmarketing studies as a means of determining the safety of newly approved drugs.
加强同类药物的对比研究，药物相互作用的研究，药物上市后的不良反应监测和药物的再评价；
Strengthen the drug comparative studies, drug interaction studies and the post-marketing surveillance of drug adverse reactions ;
应用推荐